^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CD19 CAR T cells

    i
    Other names: CD19 CAR T cells, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T Cells, CD19R(EQ)28zeta/EGFRt+ Naive and Memory T Cells, CD19R(EQ)28zetaEGFRt+ Tn/mem Cells
    Associations

    News

    Trials
    Company:
    City of Hope, National Cancer Institute
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    22d
    Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Immune cell
    |
    Calquence (acalabrutinib) • CD19 CAR T cells
    3ms
    Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, City of Hope Medical Center | Trial completion date: Aug 2025 --> Dec 2026 | Trial primary completion date: Aug 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • CD19 CAR T cells
    5ms
    Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=24, Recruiting, City of Hope Medical Center
    New P1 trial • CAR T-Cell Therapy
    |
    Erbitux (cetuximab) • cyclophosphamide • fludarabine IV • CD19 CAR T cells
    9ms
    Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
    9ms
    Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CD28 (CD28 Molecule)
    |
    CD28 expression
    |
    CD19 CAR T cells
    12ms
    Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=71, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    CD19 CAR T cells
    over1year
    Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Immune cell
    |
    Calquence (acalabrutinib) • CD19 CAR T cells
    over1year
    Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    CD28 (CD28 Molecule)
    |
    CD19 CAR T cells
    almost2years
    Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=71, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    CD19 CAR T cells
    over2years
    Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
    over2years
    Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=71, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2022 --> Sep 2022
    Enrollment closed • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    CD19 CAR T cells
    over2years
    Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, City of Hope Medical Center | N=54 --> 37 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
    over2years
    Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=88, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    CD19 CAR T cells
    over2years
    Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule) • CD28 (CD28 Molecule)
    |
    CD19 CAR T cells
    3years
    Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL) (ASH 2021)
    All but 1 patient received a fludarabine/cyclophosphamide (Flu/Cy)-based lymphodepletion regimen prior to receiving CD19CART at 1 of 2 dose levels (DL): DL1=200 million (M) and DL2=600M CAR+ T cells... This clinical study provides evidence for the safety, feasibility and efficacy of Tn/mem-derived CD19CART preceded by Flu/Cy lymphodepletion for the treatment of r/r B-NHL. We plan to pursue this CAR T cell platform in future B-NHL studies, particularly for CNS lymphoma given the encouraging safety and efficacy of CD19CART in the 5 PCNSL patients.
    Clinical • P1 data • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • CD19 CAR T cells
    over3years
    Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Sep 2023 --> Dec 2023
    Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    Calquence (acalabrutinib) • CD19 CAR T cells
    over3years
    Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=51, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule) • CD28 (CD28 Molecule)
    |
    CD19 CAR T cells
    over3years
    Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1, N=54, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    etoposide IV • fludarabine IV • CD19 CAR T cells • cyclophosphamide intravenous
    over3years
    Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=88, Recruiting, City of Hope Medical Center | Trial completion date: Sep 2022 --> Dec 2021 | Trial primary completion date: Sep 2022 --> Dec 2021
    Clinical • Trial completion date • Trial primary completion date • Minimal residual disease
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    CD19 CAR T cells
    almost4years
    Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Sep 2020 --> Jan 2021
    Clinical • Enrollment open • Trial initiation date • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    Calquence (acalabrutinib) • CD19 CAR T cells
    over4years
    Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, City of Hope Medical Center
    Clinical • New P2 trial • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule)
    |
    Calquence (acalabrutinib) • CD19 CAR T cells